Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.
about
CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying HypothesisProgress and problems in understanding and managing primary Epstein-Barr virus infectionsImmune modulation during latent herpesvirus infectionToll-like receptors: the swiss army knife of immunity and vaccine developmentInfectious MononucleosisEarly-life exposures to infectious agents and later cancer developmentEpstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causationThe criteria to confirm the role of Epstein-Barr virus in nasopharyngeal carcinoma initiationPosttransplant lymphoproliferative disease after pediatric solid organ transplantationImmune regulation of human herpesviruses and its implications for human transplantationEpstein-Barr virus infection and posttransplant lymphoproliferative disorderAdoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized miceMurid herpesvirus-4 exploits dendritic cells to infect B cellsInfectious mononucleosis.Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor LigandsEpstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapyBALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV.Progress, prospects, and problems in Epstein-Barr virus vaccine development.Murid herpesvirus-4 lacking thymidine kinase reveals route-dependent requirements for host colonization.Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challengeAntibody evasion by a gammaherpesvirus O-glycan shieldTLR-based immune adjuvants.Myeloid infection links epithelial and B cell tropisms of Murid Herpesvirus-4.An Epstein-Barr virus encoded inhibitor of Colony Stimulating Factor-1 signaling is an important determinant for acute and persistent EBV infection.Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350.Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assayPrevalence of papillomaviruses, polyomaviruses, and herpesviruses in triple-negative and inflammatory breast tumors from algeria compared with other types of breast cancer tumors.Vaccination against a hit-and-run viral cancer.Vaccination with murid herpesvirus-4 glycoprotein B reduces viral lytic replication but does not induce detectable virion neutralizationA large-scale seroprevalence of Epstein-Barr virus in Taiwan.Epstein-barr virus vaccines.Importance of antibody in virus infection and vaccine-mediated protection by a latency-deficient recombinant murine γ-herpesvirus-68The initiation and prevention of multiple sclerosis.The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development.Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated MalignanciesImpaired Epstein-Barr Virus-Specific Neutralizing Antibody Response during Acute Infectious Mononucleosis Is Coincident with Global B-Cell DysfunctionEarly T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination.Virology. Epstein-Barr virus turns 50.Epstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis.A meta-analysis of interaction between Epstein-Barr virus and HLA-DRB1*1501 on risk of multiple sclerosis
P2860
Q21296711-66F9F4FA-C7F8-4D3C-844F-29C81069B155Q24597706-EF1A4BC5-12A5-478D-877E-8EC80BA522DCQ24624044-EDB8C7EB-0842-45DD-B676-18D8395116C1Q26746644-9A10405C-BC82-45C4-AECF-F87E9B624FEDQ26783692-8EE71A14-AC19-4D43-9835-10C20660FCC3Q26786103-6329AD9B-F49E-46EA-8BA8-C1FE7C3C3B8BQ26830464-E9272EC7-33C5-4E43-8DFE-87BCB375CEDDQ26853527-40B04517-5F51-4661-8B99-3D3F8454F75AQ26866013-337DDFD2-ABD5-4F89-902E-9519D5E4120AQ26992146-A33A4E2B-EAB3-4522-9651-EEEDC73632C6Q27024229-F12EF345-72FA-4898-9D83-F33D8FB3B9DBQ27324235-4D60B70E-18B6-4E95-9FE9-664019B43C10Q27348688-6739B733-2DA6-42C8-9687-38C3EE7A0173Q28084340-C355A334-BF60-45CC-88B8-B67E516732D4Q28972540-DDDD7BFE-A291-405E-AC33-1FA505793602Q30878158-D6EE1163-EB2B-4D65-8084-0129B4AACFD4Q33798426-F4ADCA65-0662-4569-916B-54F1EC681EF2Q33812640-DCE913E6-E412-4FA4-AFEB-3FA85A58ADD6Q33910738-5928ED9E-E5FC-4A89-8F78-BEF58E379084Q34058118-79040290-495B-4752-9343-A69044FD9494Q34082672-93F83FE4-1BC7-4B9F-AB8C-20EE1BAB4E2CQ34400322-591D500F-7FDE-4234-98AC-BE4AC366EDC0Q34426495-548ED50A-4DD5-4DFC-B7FF-21EF55774D36Q34539785-5D89D4A4-EA8E-4248-B869-6B1291D6008BQ34597080-639A4568-73D8-4F89-9228-5F6E64BC3746Q34609654-7D01DA01-E752-4189-90A0-89766449E8EFQ34640608-AC15BA39-DBBA-4C99-AA31-FC67A9DC53F6Q34641583-E55E88CA-9E30-4E25-9D8C-D3DFFA7DC967Q34641914-98E013FB-2838-47F1-8F74-AECE1B9B6886Q35007123-9B4CC243-1D0C-4E97-B096-A5D8BA4E1BB4Q35053650-65C80649-98FD-4BFF-A581-5D62BA12DBBAQ35685590-6D09F526-3310-40BE-B6AB-468A122FEBFBQ35741861-0D8F51CE-0FB4-4189-AEC9-E8D8D62637E0Q35815850-26EB48B4-04A4-4466-A14B-51EA28B83D33Q35829978-9928C25F-FFD9-4805-9DA2-F000491195B3Q35913905-8AA511A8-0E0F-4F1D-8A0D-20EC9BB1F434Q35994831-31EFE894-43A2-40F4-880F-5466E09FA06BQ36088975-6546555F-61D9-44E5-88B2-6872CDE6DE53Q36206282-134ACCB9-8683-43C9-B75D-496A72D2393FQ36363968-9EB23DBA-644F-4A13-94B6-D3DFE33D4A11
P2860
Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Recombinant gp350 vaccine for ...... ccine in healthy young adults.
@ast
Recombinant gp350 vaccine for ...... ccine in healthy young adults.
@en
Recombinant gp350 vaccine for ...... ccine in healthy young adults.
@nl
type
label
Recombinant gp350 vaccine for ...... ccine in healthy young adults.
@ast
Recombinant gp350 vaccine for ...... ccine in healthy young adults.
@en
Recombinant gp350 vaccine for ...... ccine in healthy young adults.
@nl
prefLabel
Recombinant gp350 vaccine for ...... ccine in healthy young adults.
@ast
Recombinant gp350 vaccine for ...... ccine in healthy young adults.
@en
Recombinant gp350 vaccine for ...... ccine in healthy young adults.
@nl
P2093
P2860
P921
P356
P1476
Recombinant gp350 vaccine for ...... ccine in healthy young adults.
@en
P2093
Alex Bollen
Andre Moreels
Corinne Vandermeulen
Etienne M Sokal
Françoise Smets
Karel Hoppenbrouwers
Martine Denis
Michel Moutschen
Michèle Haumont
Philippe Léonard
P2860
P304
P356
10.1086/523813
P407
P577
2007-12-01T00:00:00Z